COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2020 |
| Outros Autores: | , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/43817 |
Resumo: | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica Experimental e Computacional de Fármacos. Rio de Janeiro, RJ, Brasil. |
| id |
CRUZ_2ed6a7aa66a73985ed36ce26326db853 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/43817 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Senger, Mario RobertoEvangelista, Tereza Cristina SantosDantas, Rafael FerreiraSantana, Marcos Vinicius da SilvaGonçalves, Luiz Carlos SaramagoSouza Neto, Lauro Ribeiro deFerreira, Sabrina BaptistaSilva Junior, Floriano Paes2020-10-05T18:22:56Z2020-10-05T18:22:56Z2020SENGER, Mario Roberto et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 115, p.1-32, Oct. 2020.0074-0276https://www.arca.fiocruz.br/handle/icict/4381710.1590/0074-027602002541678-8060engFundação Oswaldo Cruz. Instituto Oswaldo Cruz.COVID-19SARS-CoV-2Reposição de drogasDescoberta de drogasCiclo de replicaçãoAlvos de drogasCOVID-19SARS-CoV-2Drug repurposingDrug discoveryReplication cycleDrug targetsCOVID-19: molecular targets, drug repurposing and new avenues for drug discoveryinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica Experimental e Computacional de Fármacos. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Instituto de Química. Laboratório de Síntese Orgânica e Prospecção Biológica. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica Experimental e Computacional de Fármacos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica Experimental e Computacional de Fármacos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica Experimental e Computacional de Fármacos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica Experimental e Computacional de Fármacos. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Instituto de Química. Laboratório de Síntese Orgânica e Prospecção Biológica. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica Experimental e Computacional de Fármacos. Rio de Janeiro, RJ, Brasil.Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infection that may break the healthcare system of several countries. Here, we aimed at presenting a critical view of ongoing drug repurposing efforts for COVID-19 as well as discussing opportunities for development of new treatments based on current knowledge of the mechanism of infection and potential targets within. Finally, we also discuss patent protection issues, cost effectiveness and scalability of synthetic routes for some of the most studied repurposing candidates since these are key aspects to meet global demand for COVID-19 treatment.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/43817/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALMarioRSenger_RafaelDantas_etal_IOC_2020.pdfMarioRSenger_RafaelDantas_etal_IOC_2020.pdfapplication/pdf5499983https://www.arca.fiocruz.br/bitstream/icict/43817/2/MarioRSenger_RafaelDantas_etal_IOC_2020.pdf5932bbdfa99924aacc205f3cc755422bMD52TEXTMarioRSenger_RafaelDantas_etal_IOC_2020.pdf.txtMarioRSenger_RafaelDantas_etal_IOC_2020.pdf.txtExtracted texttext/plain151879https://www.arca.fiocruz.br/bitstream/icict/43817/3/MarioRSenger_RafaelDantas_etal_IOC_2020.pdf.txt6aa19705037f64debf640a8ee29953a7MD53icict/438172020-10-06 02:04:50.226oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352020-10-06T05:04:50Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery |
| title |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery |
| spellingShingle |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery Senger, Mario Roberto COVID-19 SARS-CoV-2 Reposição de drogas Descoberta de drogas Ciclo de replicação Alvos de drogas COVID-19 SARS-CoV-2 Drug repurposing Drug discovery Replication cycle Drug targets |
| title_short |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery |
| title_full |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery |
| title_fullStr |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery |
| title_full_unstemmed |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery |
| title_sort |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery |
| author |
Senger, Mario Roberto |
| author_facet |
Senger, Mario Roberto Evangelista, Tereza Cristina Santos Dantas, Rafael Ferreira Santana, Marcos Vinicius da Silva Gonçalves, Luiz Carlos Saramago Souza Neto, Lauro Ribeiro de Ferreira, Sabrina Baptista Silva Junior, Floriano Paes |
| author_role |
author |
| author2 |
Evangelista, Tereza Cristina Santos Dantas, Rafael Ferreira Santana, Marcos Vinicius da Silva Gonçalves, Luiz Carlos Saramago Souza Neto, Lauro Ribeiro de Ferreira, Sabrina Baptista Silva Junior, Floriano Paes |
| author2_role |
author author author author author author author |
| dc.contributor.author.fl_str_mv |
Senger, Mario Roberto Evangelista, Tereza Cristina Santos Dantas, Rafael Ferreira Santana, Marcos Vinicius da Silva Gonçalves, Luiz Carlos Saramago Souza Neto, Lauro Ribeiro de Ferreira, Sabrina Baptista Silva Junior, Floriano Paes |
| dc.subject.other.pt_BR.fl_str_mv |
COVID-19 SARS-CoV-2 Reposição de drogas Descoberta de drogas Ciclo de replicação Alvos de drogas |
| topic |
COVID-19 SARS-CoV-2 Reposição de drogas Descoberta de drogas Ciclo de replicação Alvos de drogas COVID-19 SARS-CoV-2 Drug repurposing Drug discovery Replication cycle Drug targets |
| dc.subject.en.pt_BR.fl_str_mv |
COVID-19 SARS-CoV-2 Drug repurposing Drug discovery Replication cycle Drug targets |
| description |
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica Experimental e Computacional de Fármacos. Rio de Janeiro, RJ, Brasil. |
| publishDate |
2020 |
| dc.date.accessioned.fl_str_mv |
2020-10-05T18:22:56Z |
| dc.date.available.fl_str_mv |
2020-10-05T18:22:56Z |
| dc.date.issued.fl_str_mv |
2020 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
SENGER, Mario Roberto et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 115, p.1-32, Oct. 2020. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/43817 |
| dc.identifier.issn.pt_BR.fl_str_mv |
0074-0276 |
| dc.identifier.doi.none.fl_str_mv |
10.1590/0074-02760200254 |
| dc.identifier.eissn.none.fl_str_mv |
1678-8060 |
| identifier_str_mv |
SENGER, Mario Roberto et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 115, p.1-32, Oct. 2020. 0074-0276 10.1590/0074-02760200254 1678-8060 |
| url |
https://www.arca.fiocruz.br/handle/icict/43817 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. |
| publisher.none.fl_str_mv |
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/43817/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/43817/2/MarioRSenger_RafaelDantas_etal_IOC_2020.pdf https://www.arca.fiocruz.br/bitstream/icict/43817/3/MarioRSenger_RafaelDantas_etal_IOC_2020.pdf.txt |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 5932bbdfa99924aacc205f3cc755422b 6aa19705037f64debf640a8ee29953a7 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798324670029627392 |